Nova Vision logo

Centers Offering VRT — Providing Diagnosis, Ongoing Feedback & Therapy Updates

NovaVision™ partners with qualified centers to diagnose visual field defects in stroke and brain injury patients, and if warranted recommends NovaVision VRT™ Vision Restoration Therapy™.

VRT is a clinically proven, in-home therapy performed on an FDA-cleared medical device to stimulate damaged neurons and aid in the restoration of lost vision. There's no medication and no surgery required. After six to seven months of therapy, most patients experience significant improvements in their vision and quality of life.

NovaVision works with distinguished stroke, TBI, vision and rehabilitation institutions to provide diagnostics and vision therapy to patients, and the Partner Center's administration of evaluations and oversight of the vision therapy process is key to VRT and the patient.

The number of Partner Centers offering VRT is steadily expanding. Please check back often to see the most current list of centers on our website and to keep abreast of our progress.

Interested in Offering VRT?

NovaVision VRT Vision Restoration Therapy is currently being offered at major institutions throughout the U.S., and in Germany and Singapore specializing in stroke, traumatic brain injury, vision and rehabilitation.

Please contact us if your organization would like to be considered for participation as a center offering VRT.

Learn More

News

Wall Street Journal Feature NovaVision™ VRT™ Research & Improvements for Stroke Vision Loss Patient

The Wall Street Journal Health story, Reversing Partial Blindness reports on VRT™ as "A Revolution in Neuroscience," and describes how VRT can restore the vision of patients who have suffered partial blindness as a result of a stroke or traumatic brain injury (TBI).

Research Update

Attentional Cueing Improves Vision Restoration Therapy in Patients With Visual Field Defects

In a retrospective, randomized clinical trial, treatment outcome was compared in patients with postgenicular visual system lesions who received either standard VRT or VRT with attentional cueing for a six-month trial period. Attentional cueing was found to amplify long-term neuronal plasticity.

News

ABC-NY Eyewitness News Patient Treated with VRT™ at Columbia University Medical Center

ABC-NY Eyewitness News Video Clip with On Call reporter Dr. Jay Adlersberg talks with a patient who came to the U.S. to be treated with NovaVision VRT™ Vision Restoration Therapy and physician, Dr. Randolph Marshall of the Neurological Institute of New York at Columbia Medical Center.

The Team behind NovaVision VRT Vision Restoration Therapy

Louis R. Caplan, M.D.

Professor of Neurology, Harvard Medical School Chief of the Division of Cerebrovascular Disease Department of Neurology, Beth Israel Deaconess Medical Center

Andrew Firlik, M.D.

Clinical Assistant Professor of Neurosurgery, New York University School of Medicine

Alvaro Pascual-Leone, M.D., Ph.D.

Director, Center for Non-Invasive Brain Stimulation and Professor of Neurology, Harvard Medical School and the Beth Israel Deaconess Medical Center

Misha Pless, M.D.

Director, Division General Neurology, Neuro-ophthalmology, Massachusetts General Hospital; Associate Professor of Neurology, Harvard Medical School

Vilayanur S. Ramachandran, M.D., Ph.D.

Director of the Center for Brain and Cognition, and Professor of Psychology and Neurosciences Program at University of California, San Diego

Jose G. Romano, M.D.

Associate Professor of Neurology, Cerebrovascular Division; Associate Chair for Clinical Affairs, Department of Neurology University of Miami Miller School of Medicine

Norman J. Schatz, M.D.

Professor of Neuro-Ophthalmology, University of Miami School of Medicine

Carla J. Shatz, Ph.D.

Director, BioX James H. Clark Center Stanford University

Torsten Wiesel, M.D.

Neuroscientist, Nobel Laureate President Emeritus, Rockefeller University